Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain

J Med Chem. 2022 Jan 13;65(1):485-496. doi: 10.1021/acs.jmedchem.1c01570. Epub 2021 Dec 21.

Abstract

Inhibitor cystine knot peptides, derived from venom, have evolved to block ion channel function but are often toxic when dosed at pharmacologically relevant levels in vivo. The article describes the design of analogues of ProTx-II that safely display systemic in vivo blocking of Nav1.7, resulting in a latency of response to thermal stimuli in rodents. The new designs achieve a better in vivo profile by improving ion channel selectivity and limiting the ability of the peptides to cause mast cell degranulation. The design rationale, structural modeling, in vitro profiles, and rat tail flick outcomes are disclosed and discussed.

MeSH terms

  • Animals
  • Cell Degranulation / drug effects
  • Cystine / chemistry
  • Drug Design
  • Hot Temperature
  • Mast Cells / drug effects
  • Models, Molecular
  • NAV1.7 Voltage-Gated Sodium Channel / drug effects*
  • Pain / drug therapy*
  • Pain Measurement / drug effects
  • Rats
  • Sodium Channel Blockers / chemical synthesis*
  • Sodium Channel Blockers / pharmacology*
  • Spider Venoms / chemical synthesis*
  • Spider Venoms / pharmacology

Substances

  • NAV1.7 Voltage-Gated Sodium Channel
  • ProTx-II peptide
  • Scn9a protein, rat
  • Sodium Channel Blockers
  • Spider Venoms
  • Cystine